Litigation Details for ACADIA Pharmaceuticals Inc. v. Hetero Labs Limited (D. Del. 2020)

ACADIA Pharmaceuticals Inc. v. Hetero Labs Limited (D. Del. 2020)

Docket		Date Filed	2020-07-30
Court	District Court, D. Delaware	Date Terminated	2021-05-03
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	10,449,185; 10,646,480; 7,601,740
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. Hetero Labs Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-30				External link to document
2020-07-30	1	Complaint	United States Patent Nos. 7,601,740 (“the ’740 patent”), 10,449,185 (“the ’185 patent”), and 10,646,…the ’480 patent”) (collectively “the patents-in-suit”). This action arises under the Patent Laws of the…Hetero has infringed the ’740 patent, the ’185 patent, and the ’480 patent by submitting ANDA No. 214828…of the ’740 patent is attached as Exhibit A. 30. ACADIA owns the ’740 patent. 31…of the ’185 patent is attached as Exhibit B. 32. ACADIA owns the ’185 patent. 33	External link to document
2020-07-30	14	Answer to Complaint	owner of U.S. Patent Nos. 7,601,740 (“the ʼ740 patent”), 10,449,185 (“the ʼ185 patent”), and 10,646,480… purports to be a copy of U.S. Patent No. 10,449,185 (the “ʼ185 patent”) is entitled “Formulations of… (Invalidity of U.S. Patent No. 10,449,185) The claims of the patent-in-suit are invalid and… (Non-infringement of U.S. Patent No. 10,449,185) The manufacture, use, sale, offer…Declaration of Non-Infringement of U.S. Patent No. 10,449,185) 29. Hetero USA repeats and	External link to document
2020-07-30	22	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740; 10,449, 185; 10,646,480…July 2020 3 May 2021 1:20-cv-01022 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2020-07-30	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;10,449,185 ;10,646,480. …July 2020 3 May 2021 1:20-cv-01022 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Litigation Summary and Analysis for ACADIA Pharmaceuticals Inc. v. Hetero Labs Limited (1:20-cv-01022)

Last updated: March 3, 2026

Case Overview

ACADIA Pharmaceuticals Inc. filed patent infringement suit against Hetero Labs Limited on February 14, 2020, in the United States District Court for the District of Delaware. The case (D. Del., 1:20-cv-01022) concerns allegations that Hetero Labs unlawfully infringed ACADIA's patents related to its antipsychotic drug, rexulti (brexpiprazole).

Patent Properties at Issue

ACADIA holds two patents relevant to the case:

• U.S. Patent No. 9,847,188 — covers methods of treating schizophrenia using brexpiprazole.
• U.S. Patent No. 10,342,948 — pertains to formulations and dosing methods of brexpiprazole.

Hetero Labs has filed an Abbreviated New Drug Application (ANDA) seeking approval to produce a generic version of rexulti, which prompted ACADIA's patent infringement claim.

Key Legal Claims

• Infringement of Patent Nos. 9,847,188 and 10,342,948: ACADIA alleges Hetero's proposed generic infringes method and formulation patents.
• No Invalidity Defense: As of the latest filings, Hetero has not challenged the validity of ACADIA’s patents.

Procedural Posture and Developments

• Initial Complaint (February 2020): Filed in Delaware, asserting patent rights against Hetero’s ANDA.
• Hetero’s Response (May 2020): Filed a declaratory judgment counterclaim, asserting non-infringement and invalidity.
• Claim Construction Proceedings (2021): Conducted to clarify patent scope.
• Summary Judgment Motions (2022): Filed by both parties on infringement and validity issues.
• Settlement Discussions: Occurred sporadically, but no formal settlement announced as of the last update.

Recent Activity

• Expert Discovery (2022): Focused on claim construction and infringement analysis.
• Trial Preparation: Ongoing, with scheduled pre-trial conference set for Q2 2023.
• Potential Outcomes:
  • Court finds in favor of ACADIA, injunction or monetary damages.
  • Court invalidates patents, allowing Hetero’s marketing approval.
  • Case settles before trial.

Strategic Implications

Hetero's entry into the generic rexulti market hinges on the court's ruling. A favorable decision for ACADIA would delay generics’ market entry, sustaining higher drug prices. Conversely, invalidation or non-infringement findings could accelerate Hetero’s product launch, constraining ACADIA’s market share.

Market Context and Industry Impact

ACADIA’s patents protect brexpiprazole until at least 2030, with patent extensions potentially extending exclusivity. Patent litigation in the antidepressant/antipsychotic segment remains conventional, with generic manufacturers often challenging patents to expedite market entry.

Regulatory and Patent Strategies

• ACADIA employed patent filings to extend exclusivity.
• Hetero utilized ANDA pathways to challenge patent validity and seek market entry.
• Court’s decision will influence patent strategies industry-wide, including patent term extensions and settlement tactics.

Key Dates Summary

Date	Event
February 14, 2020	Complaint filed
May 2020	Hetero files counterclaims
2021	Claim construction hearings
2022	Summary judgment motions filed
Q2 2023	Pre-trial conference scheduled

---

Key Takeaways

• Hetero Labs' challenge to ACADIA's patents could significantly influence the drug's market lifecycle.
• Court rulings on infringement and validity will determine the timing of generic competition.
• Patent litigation remains a primary tool for pharmaceutical firms seeking to extend market exclusivity.
• No final determinations have been made; litigation continues with a trial set for late 2023.
• The case exemplifies strategic patent management and litigation planning in the specialty pharmaceutical sector.

---

FAQ

1. What is the basis of ACADIA’s patent infringement claim?
ACADIA claims Hetero’s generic brexpiprazole infringes their method and formulation patents related to rexulti.

2. Has Hetero challenged the validity of ACADIA's patents?
As of the latest filings, Hetero has not filed an explicit challenge to patent validity but has asserted non-infringement and invalidity defenses.

3. What is the possible impact if the court rules in favor of ACADIA?
ACADIA could obtain an injunction blocking Hetero from marketing generic brexpiprazole and possibly claim damages.

4. How could a ruling in favor of Hetero affect ACADIA?
A ruling that invalidates patents or finds non-infringement could enable generics to enter the market sooner, reducing ACADIA’s market share and revenues.

5. When is the case expected to reach a resolution?
The scheduled pre-trial conference is for Q2 2023, with a trial set later that year. Final resolution may take several months post-trial if appeals are filed.

---

References

[1] U.S. District Court, District of Delaware. (2020). ACADIA Pharmaceuticals Inc. v. Hetero Labs Limited. Docket No. 1:20-cv-01022.